TY - JOUR
AU - Shankar-Hari, Manu; id_orcid 0000-0002-5338-2538
AU - Francois, Bruno
AU - Remy, Kenneth E
AU - Gutierrez, Cristina
AU - Pastores, Stephen
AU - Daix, Thomas
AU - Jeannet, Robin
AU - Blood, Jane
AU - Walton, Andrew H
AU - Salomao, Reinaldo
AU - Auzinger, Georg
AU - Striker, David
AU - Martin, Robert S
AU - Anand, Nitin J
AU - Bosanquet, James
AU - Blood, Teresa
AU - Brakenridge, Scott
AU - Moldawer, Lyle L
AU - Vachharajani, Vidula
AU - Yee, Cassian
AU - Dal-Pizzol, Felipe
AU - Morre, Michel
AU - Berbille, Frederique
AU - van den Brink, Marcel
AU - Hotchkiss, Richard
PY - 2025
DA - March
TI - A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19
JO - JCI Insight
VL - 10
IS - 6
DO -  https://doi.org/10.1172/jci.insight.189150
AB - BACKGROUND: Lymphopenia and failure of lymphocytes to mount an early IFN-γ response correlate with increased mortality in COVID-19. Given the essential role of CD4 helper and CD8 cytotoxic cells in eliminating viral pathogens, this profound loss in lymphocytes may impair patients' ability to eliminate the virus. IL-7 is a pleiotropic cytokine that is obligatory for lymphocyte survival and optimal function.
PB - American Society for Clinical Investigation
UR - https://www.research.ed.ac.uk/en/publications/a-randomized-double-blind-placebo-controlled-trial-of-il-7-in-cri/
KW - Coronavirus (COVID-19)
ER